---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-144470"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:49:35.948522+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics prices $325.5M public offering of 10.5M shares at $31.00 per share

## Summary
- Gross proceeds of $325.5M; net proceeds estimated at $305.4M ($351.4M if underwriters' option is fully exercised).
- Underwriters include Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities; closing expected May 24, 2024.
- Company granted 30-day option for underwriters to purchase an additional 1.575M shares at the same price.
- Net proceeds plus existing cash expected to fund operations at least into the second half of 2026.

## SEC filing metadata
- accession: 0001193125-24-144470
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312524144470/0001193125-24-144470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312524144470/d812513d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-144470
- JSON: https://secwatch.observer/filing/0001193125-24-144470.json
- Plain text: https://secwatch.observer/filing/0001193125-24-144470.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.